Saturday, September 24, 2016 8:07:58 AM
NOV: FDA NDA submit, announce new device, new sales report
1. A new cold temp dispensing device, with longer out of fridge shelf life (7 days), is shipping and replacing inventory in EU.
2. Ferring, a smaller more committed to Vitaros company like Majorelle, has taken over the Takeda, Sandoz and Latin America territories, and will start selling again in the EU, the Germany launch is important, Germany has officially been transferred to Ferring:
Aug. 10th - “ the transfer of the German marketing authorization to Ferring, a critical step in Ferring’s plan to re-launch Vitaros in this important market, has been completed,” said Richard Pascoe, Chief Executive Officer of Apricus. “Moreover, this marks the first in a series of marketing authorization transfers we anticipate will occur later this quarter(Q3) as Ferring looks to further expand the availability of Vitaros in Europe.”
3. Latin America - Approval in Argentina is in, registration in Mexico and Columbia are in, both should be approved in 2016 -then Brazil for Ferring.
4. NDA in USA submittal in Q4 16, Approval in USA mid 2017, Vitaros only has to prove safety of the permeation enhancer DDAIP, with many world approvals and safety data on 1 million doses, this should not be a problem.
5. Recordati just launched 5 more countries, expect 5 more launches by end of Q1 2017
6. Lebanon approved, expect additional launches in Mid East
7. Rayva Ex-USA or global deal w/ current partner in EU, possible 2H 2016
8. Partner deal in China/Japan
Vitaros revenue has not grown to expected levels over the last two quarters, driven primarily by decisions made by former partners to reduce and/or suspend commercialization activities in key markets.
However, we continue to see sustained Vitaros utilization in France, Italy, and Spain, where marketing efforts have been consistent over time. And we strongly believe that through the commercial efforts of Ferring, Recordati, Majorelle, and Bracco, Vitaros can regain the sales momentum in Europe that we witnessed when Vitaros was first launched.
Recent SEEL News
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 03/06/2024 10:32:04 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 09:50:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/01/2024 10:39:18 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/14/2024 09:50:49 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/06/2024 10:26:45 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 02/02/2024 11:04:12 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 09:01:23 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/30/2024 11:05:53 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:05:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 02:47:31 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/18/2024 02:47:06 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/10/2024 09:16:24 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:46:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:45:51 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:45:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 02:45:13 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/02/2024 01:10:24 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/22/2023 09:01:19 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/22/2023 01:10:14 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/20/2023 09:59:16 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 12/20/2023 09:54:15 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/18/2023 09:54:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/15/2023 09:06:26 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/04/2023 09:05:27 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM